Vizsgálati helyszín
The Center for Cancer and Blood Disorders
Fort Worth, Texas 76104, Egyesült ÁllamokMég nincs intézményhez kötve
- 12futó vizsgálat
- 6lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 18 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis12 vizsgálat
- 2. fázis4 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz7 vizsgálat
- Lezárult6 vizsgálat
- Toboroz5 vizsgálat
- Fő szponzor
- Eli Lilly and Company4 vizsgálat
- Amgen2 vizsgálat
- Eikon Therapeutics2 vizsgálat
- Biodesix, Inc.1 vizsgálat
- Bristol-Myers Squibb1 vizsgálat
- és még 8
Futó vizsgálatok
Toboroz
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
NCT07365319· 2/3. fázis· Eikon Therapeutics· Forrás
Contact: Elelta Shiferraw
Toboroz
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
NCT07422480· 3. fázis· Takeda· Forrás
Contact: Ray Page (principal investigator)
Toboroz
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Ray Page, Site 0811
Toboroz
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· 3. fázis· Pfizer· Forrás
Toboroz
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598· 3. fázis· Eli Lilly and Company· Forrás
Contact: Ray Page (principal investigator)
Fut, nem toboroz
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
NCT06246110· 2. fázis· Eikon Therapeutics· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
NCT05353257· 3. fázis· Shanghai Henlius Biotech· Forrás
Fut, nem toboroz
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
NCT05288166· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
NCT04680052· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04666038· 3. fázis· Loxo Oncology, Inc.· Forrás
Fut, nem toboroz
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
NCT04656652· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects
NCT03289780· Biodesix, Inc.· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek